Redsense announces CEO succession date
Redsense Medical announces that newly appointed Pontus Nobréus will take over as CEO of the Company starting the 1st of August 2022. Outgoing CEO Patrik Byhmer, co-founder and largest shareholder of Redsense, will transition into a new role as Chairman of the Board.
The agreement was announced in May but an exact date when Nobréus would assume responsibilities and take over the helm at Redsense was still to be determined. Nobréus combines a track record of driving sales through well-targeted commercialization with an unwavering commitment to innovation that truly benefits patients, and takes over the helm at Redsense to speed up its ongoing journey of growth.
About Pontus Nobréus
Pontus Nobréus has held leading business positions in diagnostics and medtech for more than 15 years, including employments in the United States and South Africa. Nobréus joins Redsense from a position as CEO of Pro Health Pharma Sweden AB. He previously served as CEO of Glycorex Transplantation AB (publ) and prior to that as Business Development Director at Biovica International AB. He has also worked at HemoCue and Svar Life Science, and his experience extends across sales, channel management, business development, and marketing in international settings.
Nobréus holds an MBA from Henley Business School as well as a M.Sc. in Mechanical Engineering from Lund University. In addition, he is a Certified Board Member by StyrelseAkademien.
About the leadership change
Current CEO Patrik Byhmer announced his decision to step down as CEO in response to the Nomination Committee’s decision on December 7, 2021, to propose him as new Chairman of the Board. Current Chairman Bo Unéus is proposed to retain his seat on the board with a special focus on business development, investors and international business relationships.